Aspira Women’s Health Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $2.3 million, a 2% increase from $2.26 million in the same period last year. For the nine months ending September 30, 2025, the company generated $6.99 million in revenue, up from $6.83 million in 2024. Despite this growth in revenue, the company continues to face significant challenges, posting a net loss of $4.89 million for the quarter, compared to a loss of $3.55 million in the prior year. The nine-month net loss also improved to $9.41 million from $11.71 million in 2024.
The company’s operational metrics showed a decrease in the number of OvaSuite tests performed, which fell by 5% to 5,727 tests in Q3 2025, down from 6,001 tests in Q3 2024. This decline is attributed to a reduction in the field sales team, which the company has since restructured to focus on more profitable markets. The average unit price for Ova1Plus tests increased to $407 from $381, contributing to the overall revenue growth despite the drop in test volume.
Aspira has made strategic moves to enhance its market position, including the issuance of 6.55 million shares in a private placement offering, raising approximately $2.95 million. The company also modified its March 2025 warrants, adjusting the exercise price to $0.35 and extending the expiration date to March 20231. Additionally, the company has been focusing on expanding its product offerings, particularly in the areas of endometriosis and ovarian cancer diagnostics, with ongoing development of tests like ENDOinform and OVAinform.
Despite these efforts, Aspira faces liquidity challenges, with an accumulated deficit of $540.8 million as of September 30, 2025. The company reported cash and cash equivalents of $3.81 million, which may not be sufficient to fund operations through the next twelve months without additional financing. Aspira plans to explore various funding options, including equity offerings and collaborations, to support its ongoing operations and product development initiatives. The company has expressed uncertainty about its ability to achieve profitability or positive cash flow in the near future, highlighting the need for continued strategic adjustments and capital raising efforts.
About Aspira Women's Health Inc.
Aspira Women’s Health Inc. develops and commercializes noninvasive, AI-powered diagnostic tests for gynecologic diseases, focusing on ovarian cancer and endometriosis. Its key products include the OvaSuite tests (Ova1, Overa, OvaWatch) and pipeline assays like OVAinform and ENDOinform. Serving physicians and healthcare providers primarily in the U.S., Aspira operates a CLIA-certified lab and leverages proprietary biomarker and algorithm technologies to improve early disease detection and patient risk assessment.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.